Umbilical cord blood-derived natural killer cells:

Zhi Lan Zhang, Qing Wu, Jiabin Chen, Ze Lin Zhao, Zhiqiang Cheng, Yuanyuan Jin, Chuntao Wu, Zhao Y Yang

Abstract read

In one paragraph

Article in Annals of medicine and surgery (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zhi Lan ZhangThe School of Pharmacy, North China University of Science and Technology, Tangshan, China.

Qing WuDepartment of Oncology, North China University of Science and Technology Affiliated Hospital, Tangshan, China.

Jiabin ChenThe School of Pharmacy, North China University of Science and Technology, Tangshan, China.

Ze Lin ZhaoThe School of Pharmacy, North China University of Science and Technology, Tangshan, China.

Zhiqiang ChengOncology Department of Integrated Traditional Chinese and Western Medicine, China-Japan Friendship Hospital, Beijing, China.

Yuanyuan JinNHC Key Laboratory of Biotechnology of Antibiotics, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Beijing, China.

Chuntao WuDepartment of Oncology, North China University of Science and Technology Affiliated Hospital, Tangshan, China.

Zhao Y YangNHC Key Laboratory of Biotechnology of Antibiotics, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Lung cancer remains a globally burdensome disease with high mortality. While current non-small cell lung cancer (NSCLC) treatments - surgery, chemotherapy, targeted therapy, and immune checkpoint inhibitor-based immunotherapy - have modestly improved outcomes, drug resistance and severe side effects limit efficacy, highlighting the urgent need for alternative therapies. Materials and methods: This study assessed the therapeutic potential of umbilical cord blood-derived natural killer (UCB-NK) cells in NSCLC via Results: Conclusion: UCB-NK cells hold promise as an alternative therapeutic approach for NSCLC, with the potential to combine with other therapies to improve survival and quality of life. However, large-scale clinical studies are needed to verify safety and optimize treatment protocols.

Indexed as

case reportcombination therapyimmunotherapynon-small cell lung cancerUCB-NK cells

Identifiers

PMID42433755

DOI10.1097/MS9.0000000000005014

PMCPMC13354380

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.